{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T06:39:26Z","timestamp":1775975966201,"version":"3.50.1"},"reference-count":67,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Central nervous system (CNS) disorders account for boundless socioeconomic\nburdens with devastating effects among the population, especially the elderly. The major\nsymptoms of these disorders are neurodegeneration, neuroinflammation, and cognitive\ndysfunction caused by inherited genetic mutations or by genetic and epigenetic changes\ndue to injury, environmental factors, and disease-related events. Currently available clinical\ntreatments for CNS diseases, i.e., Alzheimer\u2019s disease, Parkinson\u2019s disease, stroke,\nand brain tumor, have significant side effects and are largely unable to halt the clinical\nprogression. So gene therapy displays a new paradigm in the treatment of these disorders\nwith some modalities, varying from the suppression of endogenous genes to the expression\nof exogenous genes. Both viral and non-viral vectors are commonly used for gene\ntherapy. Viral vectors are quite effective but associated with severe side effects, like immunogenicity\nand carcinogenicity, and poor target cell specificity. Thus, non-viral vectors,\nmainly nanotherapeutics like nanoparticles (NPs), turn out to be a realistic approach\nin gene therapy, achieving higher efficacy. NPs demonstrate a new avenue in pharmacotherapy\nfor the delivery of drugs or genes to their selective cells or tissue, thus providing\nconcentrated and constant drug delivery to targeted tissues, minimizing systemic\ntoxicity and side effects. The current review will emphasize the role of NPs in mediating\ngene therapy for CNS disorders treatment. Moreover, the challenges and perspectives of\nNPs in gene therapy will be summarized.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220105122318","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T07:34:18Z","timestamp":1641454458000},"page":"304-315","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nanoparticle Mediated Gene Therapy: A Trailblazer Armament to\nFight CNS Disorders"],"prefix":"10.2174","volume":"30","author":[{"family":"Annu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New\nDelhi-110062, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleha","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New\nDelhi-110062, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Nabi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New\nDelhi-110062, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sartaj","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New\nDelhi-110062, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadab","family":"Md","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah,\nKingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PK","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences\nand Research, New Delhi-110017, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjula","family":"Baboota","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New\nDelhi-110062, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New\nDelhi-110062, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fphar.2019.00724","volume":"10","author":"Ingusci S.","year":"2019","unstructured":"Ingusci S.; Verlengia G.; Soukupova M.; Zucchini S.; Simonato M.; Gene therapy tools for brain diseases. Front Pharmacol 2019,10(724),724","journal-title":"Front Pharmacol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/14712598.2016.1114096","volume":"16","author":"Choong C-J.","year":"2016","unstructured":"Choong C-J.; Baba K.; Mochizuki H.; Gene therapy for neurological disorders. Exp Opin Biol Therap 2016,16(2),143-159","journal-title":"Exp Opin Biol Therap"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40580-018-0168-8","volume":"5","author":"Kang Y.J.","year":"2018","unstructured":"Kang Y.J.; Cutler E.G.; Cho H.; Therapeutic nanoplatforms and delivery strategies for neurological disorders. Nano Converg 2018,5(1),35","journal-title":"Nano Converg"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","volume":"28","author":"Pena S.A.","year":"2020","unstructured":"Pena S.A.; Iyengar R.; Esraghi R.S.; Bencie N.; Gene therapy for neurological disorders: Challenges and recent advancements. J Drug Targt 2020,28(2),111-128","journal-title":"J Drug Targt"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7707\/hmj.304","volume":"8","author":"Matar R.","year":"2015","unstructured":"Matar R.; Soleimani M.; Merheb M.; Human gene therapy- the future of health care. Hmadan Med J 2015,8,101-110","journal-title":"Hmadan Med J"},{"key":"ref=6","first-page":"1","volume":"17","author":"Soleimani M.","year":"2016","unstructured":"Soleimani M.; Al Zaabi A.M.; Merheb M.; Matar R.; Nanoparticles in gene therapy. Int J Integr Biol 2016,17(1),1-16","journal-title":"Int J Integr Biol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3233\/JAD-2012-120661","volume":"31","author":"P\u2019erez-Mart\u0131nez F.C.","year":"2012","unstructured":"P\u2019erez-Mart\u0131nez F.C.; Carrion B.; Cena V.; The use of nanoparticles for gene therapy in the nervous system. J Alzh Dis 2012,31(4),697-710","journal-title":"J Alzh Dis"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/17425247.2016.1188802","volume":"13","author":"Jayant R.D.","year":"2016","unstructured":"Jayant R.D.; Sosa D.; Kaushik A.; Atluri V.; Vashist A.; Current status of non-viral gene therapy for CNS disorders. Exp Opin Drug Del 2016,13(10),1433-1445","journal-title":"Exp Opin Drug Del"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.brainresbull.2009.12.008","volume":"81","author":"Huang R.","year":"2010","unstructured":"Huang R.; Ke W.; Han L.; Liu Y.; Shao K.; Jiang C.; Pei Y.; Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull 2010,81(6),600-604","journal-title":"Brain Res Bull"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ccr.2018.07.001","volume":"374","author":"Lin G.","year":"2018","unstructured":"Lin G.; Li L.; Panwar N.; Wang J.; Tjin S.C.; Wang X.; Yong K.; Non-viral gene therapy using multifunctional nanoparticles: Status, challenges, and opportunities. Coord Chem Rev 2018,374,133-152","journal-title":"Coord Chem Rev"},{"key":"ref=11","first-page":"67","volume":"18","author":"Wang D.","year":"2014","unstructured":"Wang D.; Gao G.; State-of-the-art human gene therapy: Part I. Gene delivery technologies. Discov Med 2014,18(97),67-77","journal-title":"Discov Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrg2985","volume":"12","author":"Naldini L.","year":"2011","unstructured":"Naldini L.; Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011,12(5),301-315","journal-title":"Nat Rev Genet"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/bm5003009","volume":"15","author":"Zhong Y.","year":"2014","unstructured":"Zhong Y.; Meng F.; Deng C.; Zhong Z.; Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules 2014,15(6),1955-1969","journal-title":"Biomacromolecules"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1016\/j.xphs.2019.08.027","volume":"108","author":"Annu S.R.","year":"2019","unstructured":"Annu S.R.; Rehman S.; Md S.; Baboota S.; Ali J.; Analyzing Nanotherapeutics-based approach for the management of psychotic disorders. J Pharm Sci 2019,108(12),3757-3768","journal-title":"J Pharm Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1566523220666200607185903","volume":"20","author":"Rehman S.","year":"2020","unstructured":"Rehman S.; Nabi B.; Pottoo F.H.; Baboota S.; Ali J.; Nanoparticle based gene therapy approach: A pioneering rebellion in the management of psychiatric disorders. Curr Gene Ther 2020,20(3),164-173","journal-title":"Curr Gene Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.bmc.2009.02.043","volume":"17","author":"Faraji A.H.","year":"2009","unstructured":"Faraji A.H.; Wipf P.; Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009,17(8),2950-2962","journal-title":"Bioorg Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-010-0141-7","volume":"27","author":"Yang H.","year":"2010","unstructured":"Yang H.; Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res 2010,27(9),1759-1771","journal-title":"Pharm Res"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1016\/j.biomaterials.2009.08.049","volume":"30","author":"Ke W.","year":"2009","unstructured":"Ke W.; Shao K.; Huang R.; Han L.; Liu Y.; Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol modified polyamidoamine dendrimer. Biomaterials 2009,30(36),6976-6985","journal-title":"Biomaterials"},{"key":"ref=19","author":"Montensinos R.N.","year":"2017","unstructured":"Montensinos R.N.; Liposomal drug delivery to the central nervous system. Book Chapter Liposomes 2017","journal-title":"Book Chapter Liposomes"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1039\/c3bm60030k","volume":"1","author":"Newland B.","year":"2013","unstructured":"Newland B.; Dowd E.; Pandit A.; Biomaterial approaches to gene therapies for neurodegenerative disorders of the CNS. Biomater Sci 2013,1(6),556-576","journal-title":"Biomater Sci"},{"key":"ref=21","first-page":"47","author":"Annu S.A.","year":"2021","unstructured":"Annu S.A.; Nanocarriers for the delivery of combination drugs (Liposomal nanocarriers for delivery of combination drugs) Micro  2021,47-83","journal-title":"Micro"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jconrel.2015.12.034","volume":"223","author":"Mead B.P.","year":"2016","unstructured":"Mead B.P.; Mastorakos P.; Suk J.S.; Klibanov A.L.; Hanes J.; Price R.J.; Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound. J Control Release 2016,223,109-117","journal-title":"J Control Release"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/smll.201502554","volume":"12","author":"Mastorakos P.","year":"2016","unstructured":"Mastorakos P.; Song E.; Zhang C.; Berry S.; Park H.W.; Kim Y.E.; Park J.S.; Lee S.; Suk J.S.; Hanes J.; Biodegradable DNA Nanoparticles that provide widespread gene delivery in the brain. Small 2016,12(5),678-685","journal-title":"Small"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"11609","DOI":"10.1021\/acsami.0c22112","volume":"13","author":"Li R.","year":"2021","unstructured":"Li R.; Li Y.; Mu M.; Yang B.; Chen X.; Lee W.Y.W.; Ke Y.; Yung W.H.; Tang B.Z.; Bian L.; Multifunctional nanoprobe for the delivery of therapeutic siRNA and real-time molecular imaging of Parkinson\u2019s disease biomarkers. ACS Appl Mater Interfaces 2021,13(10),11609-11620","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.7150\/thno.16562","volume":"7","author":"Niu S.","year":"2017","unstructured":"Niu S.; Zhang L-K.; Zhang L.; Zhuang S.; Zhan X.; Chen W.Y.; Du S.; Yin L.; You R.; Li C.H.; Guan Y.Q.; Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson\u2019s disease model. Theranostics 2017,7(2),344-356","journal-title":"Theranostics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jmst.2019.10.013","volume":"43","author":"Xue Y.","year":"2020","unstructured":"Xue Y.; Wang N.; Zeng Z.; Huang J.; Xaing Z.; Guan Y-Q.; Neuroprotective effect of chitosan nanoparticle gene delivery system grafted with acteoside (ACT) in Parkinson\u2019s disease models. J Mater Sci Technol 2020,43,197-207","journal-title":"J Mater Sci Technol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.actbio.2016.12.048","volume":"54","author":"Abid Sheikh M.","year":"2016","unstructured":"Abid Sheikh M.; Malik Y.S.; Xing Z.; Guo Z.; Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson\u2019s Disease (PD). Acta Biomater 2016,54,58-68","journal-title":"Acta Biomater"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"118449","DOI":"10.1016\/j.ijpharm.2019.118449","volume":"567","author":"Gan L.","year":"2019","unstructured":"Gan L.; Li Z.; Lv Q.; Huang W.; Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinson\u2019s disease model. Int J Pharm 2019,567,118449","journal-title":"Int J Pharm"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbrc.2016.10.141","volume":"482","author":"Long L.","year":"2017","unstructured":"Long L.; Cai X.; Guo R.; Wang P.; Treatment of Parkinson\u2019s disease in rats by Nrf2 transfection using MRI-guided focused ultrasound delivery of nanomicrobubbles. Biochem Biophys Res Commun 2017,482(1),75-80","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/cns.12176","volume":"20","author":"Liu Y-Y.","year":"2014","unstructured":"Liu Y-Y.; Yang X-Y.; Li Z.; Liu Z-L.; Cheng D.; Wang Y.; Wen X.J.; Hu J.Y.; Liu J.; Wang L.M.; Wang H.J.; Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson\u2019s disease. CNS Neurosci Ther 2014,20(1),76-85","journal-title":"CNS Neurosci Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e1256855","DOI":"10.1080\/23262133.2016.1256855","volume":"3","author":"Saraiva C.","year":"2016","unstructured":"Saraiva C.; Ferreira L.; Bernardino L.; Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson\u2019s disease. Neurogenesis (Austin) 2016,3(1),e1256855","journal-title":"Neurogenesis (Austin)"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12035-018-1109-6","volume":"56","author":"Aly A.E.E.","year":"2018","unstructured":"Aly A.E.E.; Harmon B.T.; Padegimas L.; Sesenoglu-Laird O.; Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the rat 6-Hydroxydopamine model of Parkinson\u2019s disease. Mol Neurobiol 2018,56(1),688-701","journal-title":"Mol Neurobiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","volume":"9","author":"Helmschrodt C","year":"2017","unstructured":"Helmschrodt C; Hobel S; Sch&#xF6;niger S; Bauer A; Polyethylenimine nanoparticle-mediated siRNA delivery to reduce a-Synuclein expression in a model of Parkinson\u2019s disease. Mol Therp Nucleic Acid 2017,9,57-68","journal-title":"Mol Therp Nucleic Acid"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1039\/C7NR06976F","volume":"10","author":"Chung T-H.","year":"2018","unstructured":"Chung T-H.; Hsu S.C.; Wu S-H.; Hsiao J-K.; Lin C.P.; Yao M.; Huang D.M.; Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson\u2019s disease. Nanoscale 2018,10(6),2998-3007","journal-title":"Nanoscale"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fgeed.2020.00004","volume":"2","author":"Stepanichev M.","year":"2020","unstructured":"Stepanichev M.; Gene editing and Alzheimer\u2019s disease: Is there light at the end of the tunnel? Front Genome Ed 2020,2,4","journal-title":"Front Genome Ed"},{"key":"ref=36","first-page":"8147080","volume":"2020","author":"Lamyaa M.K.","year":"2020","unstructured":"Lamyaa M.K.; Nada A.; Ibrahim S.; Ayesha F.; Nanoparticle therapy is a promising approach in the management and prevention of many diseases: Does it help in curing Alzheimer disease. J Nanotech 2020,2020,8147080","journal-title":"J Nanotech"},{"key":"ref=37","unstructured":"First-in-human clinical trial to assess gene therapy for Alzheimer\u2019s disease. UC San Diego Health Available from:"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.11.060","volume":"80","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; An S.; Li J.; Kuang Y.; He X.; Guo Y.; Ma H.; Zhang Y.; Ji B.; Jiang C.; Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer\u2019s disease mice. Biomaterials 2016,80,33-45","journal-title":"Biomaterials"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1080\/10717544.2020.1775724","volume":"27","author":"Lopez-Barbosa N.","year":"2020","unstructured":"Lopez-Barbosa N.; Garcia J.G.; Cifuentes J.; Castro L.M.; Vargas F.; Ostos C.; Cardona-Gomez G.P.; Hernandez A.M.; Cruz J.C.; Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer\u2019s. Drug Deliv 2020,27(1),864-875","journal-title":"Drug Deliv"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11095-019-2691-7","volume":"36","author":"Dos Santos Rodrigues B.","year":"2019","unstructured":"Dos Santos Rodrigues B.; Kanekiyo T.; Singh J.; ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles. Pharm Res 2019,36(11),161","journal-title":"Pharm Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","volume":"152","author":"Rassu G","year":"2017","unstructured":"Rassu G; Soddu E; Posadino AM; Pintus G; Nose- to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy. Coll Surf B Biointerf 2017,152,296-301","journal-title":"Coll Surf B Biointerf"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","volume":"279","author":"Wang P.","year":"2018","unstructured":"Wang P.; Zheng X.; Guo Q.; Yang P.; Pang X.; Qian K.; Lu W.; Zhang Q.; Jiang X.; Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease. J Control Release 2018,279,220-233","journal-title":"J Control Release"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.nano.2018.10.013","volume":"18","author":"Li R.","year":"2019","unstructured":"Li R.; Huang Y.; Chen L.; Zhou H.; Zhang M.; Targeted delivery of Intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke. Nanomedicine 2019,18,380-390","journal-title":"Nanomedicine"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e1902011","DOI":"10.1002\/smll.201902011","volume":"15","author":"Ma J.","year":"2019","unstructured":"Ma J.; Zhang S.; Liu J.; Liu F.; Du F.; Li M.; Chen A.T.; Bao Y.; Suh H.W.; Avery J.; Deng G.; Zhou Y.; Wu P.; Sheth K.; Wang H.; Zhou J.; Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membrane of engineered neural stem cells. Small 2019,15(35),e1902011","journal-title":"Small"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1039\/C8BM01621F","volume":"7","author":"Oh J.","year":"2019","unstructured":"Oh J.; Lee J.; Piao C.; Jeong J.H.; Lee M.; A self-assembled DNA-nanoparticle with a targeting peptide for hypoxia-inducible gene therapy of ischemic stroke. Biomater Sci 2019,7(5),2174-2190","journal-title":"Biomater Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijpharm.2013.07.019","volume":"454","author":"Kuang Y.","year":"2013","unstructured":"Kuang Y.; An S.; Guo Y.; Huang S.; Shao K.; Liu Y.; Li J.; Ma H.; Jiang C.; T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm 2013,454(1),11-20","journal-title":"Int J Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.7150\/thno.15297","volume":"6","author":"Fan C-H.","year":"2016","unstructured":"Fan C-H.; Cheng Y-H.; Ting C-Y.; Ho Y.J.; Hsu P.H.; Liu H.L.; Yeh C.K.; Ultrasound\/magnetic targeting with SPIO-DOX-Microbubble complex for image-guided drug delivery in brain tumors. Theranostics 2016,6(10),1542-1556","journal-title":"Theranostics"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/IJN.S286221","volume":"16","author":"Yang Q.","year":"2021","unstructured":"Yang Q.; Zhou Y.; Chen J.; Huang N.; Wang Z.; Cheng Y.; gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. Int J Nanomedicine 2021,16,185-199","journal-title":"Int J Nanomedicine"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"435101","DOI":"10.1088\/0957-4484\/22\/43\/435101","volume":"22","author":"Li J.","year":"2011","unstructured":"Li J.; Gu B.; Meng Q.; Yan Z.; Gao H.; Chen X.; Yang X.; Lu W.; The use of myristic acid as a ligand of polyethylenimine\/DNA nanoparticles for targeted gene therapy of glioblastoma. Nanotechnology 2011,22(43),435101","journal-title":"Nanotechnology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/nn504905q","volume":"9","author":"Mangraviti A.","year":"2015","unstructured":"Mangraviti A.; Tzeng S.Y.; Kozielski K.L.; Wang Y.; Jin Y.; Gullotti D.; Pedone M.; Buaron N.; Liu A.; Wilson D.R.; Hansen S.K.; Rodriguez F.J.; Gao G.D.; DiMeco F.; Brem H.; Olivi A.; Tyler B.; Green J.J.; Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano 2015,9(2),1236-1249","journal-title":"ACS Nano"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/adhm.201500563","volume":"4","author":"Wang K.","year":"2015","unstructured":"Wang K.; Kievit F.M.; Jeon M.; Silber J.R.; Ellenbogen R.G.; Zhang M.; Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma. Adv Healthc Mater 2015,4(17),2719-2726","journal-title":"Adv Healthc Mater"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","volume":"10","author":"Chen W.","year":"2020","unstructured":"Chen W.; Hu Y.; Ju D.; Gene therapy for neurodegenerative disorders: Advances, insights and prospects. Acta Pharm Sin B 2020,10(8),1347-1359","journal-title":"Acta Pharm Sin B"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jneumeth.2018.10.015","volume":"311","author":"Barnabas W.","year":"2019","unstructured":"Barnabas W.; Drug targeting strategies into the brain for treating neurological diseases. J Neurosci Methods 2019,311,133-146","journal-title":"J Neurosci Methods"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.2147\/IJN.S215941","volume":"14","author":"Dos Santos Rodrigues B.","year":"2019","unstructured":"Dos Santos Rodrigues B.; Lakkadwala S.; Kanekiyo T.; Singh J.; Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Int J Nanomedicine 2019,14,6497-6517","journal-title":"Int J Nanomedicine"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/1566523214666140120121733","volume":"14","author":"Pardo J.","year":"2014","unstructured":"Pardo J.; Morel G.R.; Astiz M.; Schwerdt J.I.; Le&#xF3;n M.L.; Rodr&#xED;guez S.S.; Here&#xF1;&#xFA; C.B.; Goya R.G.; Gene therapy and cell reprogramming for the aging brain: Achievements and promise. Curr Gene Ther 2014,14(1),24-34","journal-title":"Curr Gene Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-neuro-071013-014048","volume":"37","author":"Sternson S.M.","year":"2014","unstructured":"Sternson S.M.; Roth B.L.; Chemogenetic tools to interrogate brain functions. Annu Rev Neurosci 2014,37,387-407","journal-title":"Annu Rev Neurosci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e107603","DOI":"10.1371\/journal.pone.0107603","volume":"9","author":"Langiu M.","year":"2014","unstructured":"Langiu M.; Dadparvar M.; Kreuter J.; Ruonala M.O.; Human serum albumin-based nanoparticle-mediated in vitro gene delivery. PLoS One 2014,9(9),e107603","journal-title":"PLoS One"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1021\/acsnano.8b08177","volume":"13","author":"Erel-Akbaba G.","year":"2019","unstructured":"Erel-Akbaba G.; Carvalho L.A.; Tian T.; Zinter M.; Akbaba H.; Obeid P.J.; Chiocca E.A.; Weissleder R.; Kantarci A.G.; Tannous B.A.; Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. ACS Nano 2019,13(4),4028-4040","journal-title":"ACS Nano"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/adhm.201400800","volume":"4","author":"Mastorakos P.","year":"2015","unstructured":"Mastorakos P.; Zhang C.; Berry S.; Oh Y.; Lee S.; Eberhart C.G.; Woodworth G.F.; Suk J.S.; Hanes J.; Highly PEGylated DNA nanoparticles provide uniform and widespread gene transfer in the brain. Adv Healthc Mater 2015,4(7),1023-1033","journal-title":"Adv Healthc Mater"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"Mendell J.R.","year":"2017","unstructured":"Mendell J.R.; Al-Zaidy S.; Shell R.; Arnold W.D.; Rodino-Klapac L.R.; Prior T.W.; Lowes L.; Alfano L.; Berry K.; Church K.; Kissel J.T.; Nagendran S.; L\u2019Italien J.; Sproule D.M.; Wells C.; Cardenas J.A.; Heitzer M.D.; Kaspar A.; Corcoran S.; Braun L.; Likhite S.; Miranda C.; Meyer K.; Foust K.D.; Burghes A.H.M.; Kaspar B.K.; Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017,377(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"Adams D.","year":"2018","unstructured":"Adams D.; Gonzalez-Duarte A.; O\u2019Riordan W.D.; Yang C.C.; Ueda M.; Kristen A.V.; Tournev I.; Schmidt H.H.; Coelho T.; Berk J.L.; Lin K.P.; Vita G.; Attarian S.; Plant&#xE9;-Bordeneuve V.; Mezei M.M.; Campistol J.M.; Buades J.; Brannagan T.H.; Kim B.J.; Oh J.; Parman Y.; Sekijima Y.; Hawkins P.N.; Solomon S.D.; Polydefkis M.; Dyck P.J.; Gandhi P.J.; Goyal S.; Chen J.; Strahs A.L.; Nochur S.V.; Sweetser M.T.; Garg P.P.; Vaishnaw A.K.; Gollob J.A.; Suhr O.B.; Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018,379(1),11-21","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"Pardridge W.M.","year":"2020","unstructured":"Pardridge W.M.; Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci 2020,11,373","journal-title":"Front Aging Neurosci"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1089\/hum.2018.069","volume":"29","author":"Liang X.","year":"2018","unstructured":"Liang X.; Liu L.; Wei Y-Q.; Gao G.; Wei X.; Toxicity and efficacy of nanoparticle-mediated gene therapy in clinical study. Hum Gene Ther 2018,29(11),1227-1234","journal-title":"Hum Gene Ther"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.3390\/ijms20215491","volume":"20","author":"Patil S.","year":"2019","unstructured":"Patil S.; Gao Y-G.; Lin X.; Li Y.; Dang K.; Tian Y.; Zhang W.J.; Jiang S.F.; Qadir A.; Qian A.R.; The development of functional non-viral vectors for gene delivery. Int J Mol Sci 2019,20(21),5491-5498","journal-title":"Int J Mol Sci"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1039\/D0BM01359E","volume":"9","author":"Verma P.","year":"2021","unstructured":"Verma P.; Srivastava A.; Srikanth C.V.; Bajaj A.; Nanoparticle-mediated gene therapeutic strategies for mitigating the inflammatory bowel disease. Biomater Sci 2021,9,1481-1502","journal-title":"Biomater Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.phrs.2016.07.007","volume":"111","author":"Vago R.","year":"2016","unstructured":"Vago R.; Collico V.; Zuppone S.; Prosperi D.; Colombo M.; Nanoparticle-mediated delivery of suicide genes in cancer therapy. Pharmacol Res 2016,111,619-641","journal-title":"Pharmacol Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-12-800148-6.00005-5","volume":"88","author":"Wang Y.","year":"2014","unstructured":"Wang Y.; Huang L.; Composite nanoparticles for gene delivery. Adv Genet 2014,88,111-137","journal-title":"Adv Genet"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220105122318","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/199998\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220105122318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:53:49Z","timestamp":1693670029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/199998\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220105122318","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}